Current Report Filing (8-k)
June 06 2023 - 6:01AM
Edgar (US Regulatory)
0001759186
false
0001759186
2023-06-05
2023-06-05
0001759186
us-gaap:CommonStockMember
2023-06-05
2023-06-05
0001759186
us-gaap:WarrantMember
2023-06-05
2023-06-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
June 5, 2023
_____________________
COEPTIS THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its
charter)
| Delaware |
001-39669 |
98-1465952 |
|
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
| |
|
|
|
105 Bradford Rd, Suite 420
Wexford, Pennsylvania |
|
15090 |
| (Address of principal executive offices) |
|
(Zip Code) |
724-934-6467
(Registrant’s telephone number, including area code)
____________________________________________________________
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
|
Common Stock, par value $0.0001 per share |
|
COEP
|
|
Nasdaq Global Market |
| Warrants,
each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share |
|
COEPW |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 7.01 |
Regulation FD Disclosure |
On June 5, 2023, Coeptis Therapeutics Holdings,
Inc. (the “Company” or “Coeptis”) began making presentations to investors using an investor presentation deck
(the “Presentation”), a copy of which Presentation is included as Exhibit 99.1 to this Current Report on Form 8-K.
The Company intends to use the Presentation in
presentations to investors and analysts from time to time in the future, including in connection with current investor discussions. The
furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination by the Company
that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before
making an investment decision with respect to any security of the Company. The information in the materials is presented as of June 5,
2023, and the Company does not assume any obligation to update such information in the future.
The information in Item 7.01 of this Current Report on Form 8-K shall
not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Coeptis Therapeutics Holdings, Inc. |
| |
|
|
| Date: June 5, 2023 |
By: |
/s/ David Mehalick |
| |
|
David Mehalick
Chief Executive Officer |
Bull Horn (NASDAQ:BHSE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bull Horn (NASDAQ:BHSE)
Historical Stock Chart
From Nov 2023 to Nov 2024
